Sickle cell disease (SCD) is an inherited disease caused by the production of abnormal hemoglobin (Hb) S, whose deoxygenation-induced polymerization results in red blood cell (RBC) sickling and numerous pathophysiological consequences. SCD affects approximately 300,000 newborns worldwide each year and is associated with acute and chronic complications, including frequent painful vaso-occlusive episodes that often require hospitalization. Chronic intravascular hemolysis in SCD significantly reduces vascular nitric oxide (NO) bioavailability, consequently decreasing intracellular signaling via cyclic guanosine monophosphate (cGMP), in turn diminishing vasodilation and contributing to the inflammatory mechanisms that trigger vaso-occlusive processes. Oxidative stress may further reduce NO bioavailability in SCD and can oxidize the intracellular enzyme target of NO, soluble guanylate cyclase (sGC), rendering it inactive. Increasing intracellular cGMP-dependent signaling constitutes an important pharmacological therapeutic approach for SCD with a view to augmenting vasodilation, and reducing inflammatory mechanisms, as well as for increasing the production of anti-polymerizing fetal Hb in erythroid cells. Pharmacological agents under pre-clinical and clinical investigation for SCD include NO-based therapeutics to augment NO bioavailability, as well as heme-dependent sGC stimulators and heme-independent sGC activators that directly stimulate native and oxidized sGC, respectively, therefore bypassing the need for vascular NO delivery. Additionally, the phosphodiesterases (PDEs) that degrade intracellular cyclic nucleotides with specific cellular distributions are attractive drug targets for SCD; PDE9 is highly expressed in hematopoietic cells, making the use of PDE9 inhibitors, originally developed for use in neurological diseases, a potential approach that could rapidly amplify intracellular cGMP concentrations in a relatively tissue-specific manner.
Impact statement
Sickle cell disease (SCD) is one of the most common inherited diseases and is associated with a reduced life expectancy and acute and chronic complications, including frequent painful vaso-occlusive episodes that often require hospitalization. At present, treatment of SCD is limited to hematopoietic stem cell transplant, transfusion, and limited options for pharmacotherapy, based principally on hydroxyurea therapy. This review highlights the importance of intracellular cGMP-dependent signaling pathways in SCD pathophysiology; modulation of these pathways with soluble guanylate cyclase (sGC) stimulators or phosphodiesterase (PDE) inhibitors could potentially provide vasorelaxation and anti-inflammatory effects, as well as elevate levels of anti-sickling fetal hemoglobin.
PielFBSteinbergMHReesDC.Sickle cell disease. N Engl J Med2017;
376:1561–73
4.
BrittenhamGMSchechterANNoguchiCT.Hemoglobin S polymerization: primary determinant of the hemolytic and clinical severity of the sickling syndromes. Blood1985;
65:183–9
ConranNBelcherJD.Inflammation in sickle cell disease. Clin Hemorheol Microcirc2018;
68:263–99
7.
BallasSKLieffSBenjaminLJ, Dampier CD, Heeney MM, Hoppe C, Johnson CS, Rogers ZR, Smith-Whitley K, Wang WC, Telen MJ.
Definitions of the phenotypic manifestations of sickle cell disease. Am J Hematol2010;
85:6–13
8.
HebbelRP.Ischemia-reperfusion injury in sickle cell anemia: relationship to acute chest syndrome, endothelial dysfunction, arterial vasculopathy, and inflammatory pain. Hematol Oncol Clin North Am2014;
28:181–98
9.
KatoGJSteinbergMHGladwinMT.Intravascular hemolysis and the pathophysiology of sickle cell disease. J Clin Invest2017;
127:750–60
10.
NottageKEsteppJHankinsJS.Future perspectives for the treatment of sickle cell anemia. In: CostaFFConranN (eds) Sickle cell anemia: from basic science to clinical practice.
Switzerland:
Springer International, 2016, pp.399–429
11.
HebbelRP.Reconstructing sickle cell disease: a data-based analysis of the “hyperhemolysis paradigm” for pulmonary hypertension from the perspective of evidence-based medicine. Am J Hematol2011;
86:123–54
12.
ReiterCDWangXTanus-SantosJEHogg N, Cannon RO, Schechter AN, Gladwin MT.
Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med2002;
8:1383–9
13.
FigueiredoRTFernandezPLMourao-SaDSPorto BN, Dutra FF, Alves LS, Oliveira MF, Oliveira PL, Graça-Souza AV, Bozza MT.
Characterization of heme as activator of Toll-like receptor 4. J Biol Chem2007;
282:20221–9
14.
DutraFFAlvesLSRodriguesDFernandez PL, de Oliveira RB, Golenbock DT, Zamboni DS, Bozza MT.
Hemolysis-induced lethality involves inflammasome activation by heme. Proc Natl Acad Sci U S A2014;
111:E4110–8
15.
MerleNSGrunenwaldARajaratnamHGnemmi V, Frimat M, Figueres ML, Knockaert S, Bouzekri S, Charue D, Noe R, Robe-Rybkine T, Le-Hoang M, Brinkman N, Gentinetta T, Edler M, Petrillo S, Tolosano E, Miescher S, Le Jeune S, Houillier P, Chauvet S, Rabant M, Dimitrov JD, Fremeaux-Bacchi V, Blanc-Brude OP, Roumenina LT.
Intravascular hemolysis activates complement via cell-free heme and heme-loaded microvesicles. JCI Insight2018;
3:pii:96910
16.
ChenGZhangDFuchsTAManwaniDWagnerDDFrenettePS.Heme-induced neutrophil extracellular traps contribute to the pathogenesis of sickle cell disease. Blood2014;
123:3818–27
17.
GhoshSAdisaOAChappaPTan F, Jackson KA, Archer DR, Ofori-Acquah SF.
Extracellular hemin crisis triggers acute chest syndrome in sickle mice. J Clin Invest2013;
123:4809–20
18.
VallelianFSchaerCADeuelJWIngoglia G, Humar R, Buehler PW, Schaer DJ.
Revisiting the putative role of heme as a trigger of inflammation. Pharmacol Res Perspect2018;
6:e00392
19.
VendrameFOlopsLSaadSTOCostaFFFertrinKY.Differences in heme and hemopexin content in lipoproteins from patients with sickle cell disease. J Clin Lipidol2018;12:1532-8
20.
SantiagoRPGuardaCCFigueiredoCVBFiuza LM, Aleluia MM, Adanho CSA, Carvalho MOS, Pitanga TN, Zanette DL, Lyra IM, Nascimento VML, Vercellotti GM, Belcher JD, Gonçalves MS.
Serum haptoglobin and hemopexin levels are depleted in pediatric sickle cell disease patients. Blood Cells Mol Dis2018;
72:34–6
21.
SoloveyASomaniABelcherJDMilbauer L, Vicent L, Pawlinski R, Nath KA, Kelm RJ Jr, Mackman N, O'Sullivan MG, Gupta K, Vercellotti GM, Hebbel RP.
A monocyte-TNF-endothelial activation axis in sickle transgenic mice: therapeutic benefit from TNF blockade. Am J Hematol2017;
92:1119–30
22.
TurhanAJenabPBruhnsPRavetchJVCollerBSFrenettePS.Intravenous immune globulin prevents venular vaso-occlusion in sickle cell mice by inhibiting leukocyte adhesion and the interactions between sickle erythrocytes and adherent leukocytes. Blood2004;
103:2397–400
23.
ZhangDXuCManwaniDFrenettePS.Neutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology. Blood2016;
127:801–9
24.
HebbelRPBoogaertsMAEatonJWSteinbergMH.Erythrocyte adherence to endothelium in sickle-cell anemia. A possible determinant of disease severity. N Engl J Med1980;
302:992–5
25.
HebbelRPYamadaOMoldowCFJacobHSWhiteJGEatonJW.Abnormal adherence of sickle erythrocytes to cultured vascular endothelium: possible mechanism for microvascular occlusion in sickle cell disease. J Clin Invest1980;
65:154–60
26.
BennewitzMFJimenezMAVatsRTutuncunoglu E, Jonassaint J, Kato GJ, Gladwin MT, Sundd PP.
Lung vaso-occlusion in sickle cell disease mediated by arteriolar neutrophil-platelet microemboli. JCI Insight2017;
2:e89761
ArnoldWPMittalCKKatsukiSMuradF.Nitric oxide activates guanylate cyclase and increases guanosine 3':5'-cyclic monophosphate levels in various tissue preparations. Proc Natl Acad Sci U S A1977;
74:3203–7
30.
YaoXHuangY.From nitric oxide to endothelial cytosolic Ca2+: a negative feedback control. Trends Pharmacol Sci2003;
24:263–6
31.
RobertsWRibaRHomer-VanniasinkamSFarndaleRWNaseemKM.Nitric oxide specifically inhibits integrin-mediated platelet adhesion and spreading on collagen. J Thromb Haemost2008;
6:2175–85
32.
SalveminiDMasiniEAnggardEMannaioniPFVaneJ.Synthesis of a nitric oxide-like factor from L-arginine by rat serosal mast cells: stimulation of guanylate cyclase and inhibition of platelet aggregation. Biochem Biophys Res Commun1990;
169:596–601
33.
MarcondesSCardosoMHMorgantiRPThomazzi SM, Lilla S, Murad F, De Nucci G, Antunes E.
Cyclic GMP-independent mechanisms contribute to the inhibition of platelet adhesion by nitric oxide donor: a role for alpha-actinin nitration. Proc Natl Acad Sci U S A2006;
103:3434–9
34.
IgnarroLJ.Haem-dependent activation of guanylate cyclase and cyclic GMP formation by endogenous nitric oxide: a unique transduction mechanism for transcellular signaling. Pharmacol Toxicol1990;
67:1–7
35.
NiuXFSmithCWKubesP.Intracellular oxidative stress induced by nitric oxide synthesis inhibition increases endothelial cell adhesion to neutrophils. Circ Res1994;
74:1133–40
36.
HossainMQadriSMLiuL.Inhibition of nitric oxide synthesis enhances leukocyte rolling and adhesion in human microvasculature. J Inflamm2012;
9:28
37.
ConranNFerreiraHHLorand-MetzeIThomazziSMAntunesEde NucciG.Nitric oxide regulates human eosinophil adhesion mechanisms in vitro by changing integrin expression and activity on the eosinophil cell surface. Br J Pharmacol2001;
134:632–8
38.
DavenpeckKLGauthierTWLeferAM.Inhibition of endothelial-derived nitric oxide promotes P-selectin expression and actions in the rat microcirculation. Gastroenterology1994;
107:1050–8
39.
De CaterinaRLibbyPPengHBThannickal VJ, Rajavashisth TB, Gimbrone MA Jr, Shin WS, Liao JK.
Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest1995;
96:60–8
40.
Kim-ShapiroDBGladwinMT.Nitric oxide pathology and therapeutics in sickle cell disease. Clin Hemorheol Microcirc2018;
68:223–37
41.
MorrisCRKatoGJPoljakovicMWang X, Blackwelder WC, Sachdev V, Hazen SL, Vichinsky EP, Morris SM Jr, Gladwin MT.
Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA2005;
294:81–90
42.
AslanMRyanTMAdlerBTownes TM, Parks DA, Thompson JA, Tousson A, Gladwin MT, Patel RP, Tarpey MM, Batinic-Harbele I, White CR, Freeman BA.
Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease. Proc Natl Acad Sci U S A2001;
98:15215–20
43.
UsmaniAMachadoRF.Vascular complications of sickle cell disease. Clin Hemorheol Microcirc2018;
68:205–21
44.
WoodKCGrangerDN.Sickle cell disease: role of reactive oxygen and nitrogen metabolites. Clin Exp Pharmacol Physiol2007;
34:926–32
45.
ReesDCCerviP, GrimwadeDO'Driscoll A, Hamilton M, Parker NE, Porter JB.
The metabolites of nitric oxide in sickle-cell disease. Br J Haematol1995;
91:834–7
46.
FrenchJA2ndKennyDScottJPHoffman RG, Wood JD, Hudetz AG, Hillery CA.
Mechanisms of stroke in sickle cell disease: sickle erythrocytes decrease cerebral blood flow in rats after nitric oxide synthase inhibition. Blood1997;
89:4591–9.
47.
LopezBLKreshakAAMorrisCRDavis-MoonLBallasSKMaXL.L-arginine levels are diminished in adult acute vaso-occlusive sickle cell crisis in the emergency department. Br J Haematol2003;
120:532–4
48.
MinneciPCDeansKJZhiHYuen PS, Star RA, Banks SM, Schechter AN, Natanson C, Gladwin MT, Solomon SB.
Hemolysis-associated endothelial dysfunction mediated by accelerated NO inactivation by decompartmentalized oxyhemoglobin. J Clin Invest2005;
115:3409–17
49.
IkutaTThatteHSTangJXMukerji I, Knee K, Bridges KR, Wang S, Montero-Huerta P, Joshi RM, Head CA.
Nitric oxide reduces sickle hemoglobin polymerization: potential role of nitric oxide-induced charge alteration in depolymerization. Arch Biochem Biophys2011;
510:53–61
50.
PritchardKAJr.OuJOuZShi Y, Franciosi JP, Signorino P, Kaul S, Ackland-Berglund C, Witte K, Holzhauer S, Mohandas N, Guice KS, Oldham KT, Hillery CA.
Hypoxia-induced acute lung injury in murine models of sickle cell disease. Am J Physiol Lung Cell Mol Physiol2004;
286:L705–14.
51.
MozarAConnesPCollinsBHardy-Dessources MD, Romana M, Lemonne N, Bloch W, Grau M.
Red blood cell nitric oxide synthase modulates red blood cell deformability in sickle cell anemia. Clin Hemorheol Microcirc2016;
64:47–53
52.
SpaceSLLanePAPickettCKWeilJV.Nitric oxide attenuates normal and sickle red blood cell adherence to pulmonary endothelium. Am J Hematol2000;
63:200–4
53.
GutsaevaDRMontero-HuertaPParkersonJBYerigenahallySDIkutaTHeadCA.Molecular mechanisms underlying synergistic adhesion of sickle red blood cells by hypoxia and low nitric oxide bioavailability. Blood2014;
123:1917–26
54.
CanalliAAFranco-PenteadoCFSaadSTConranNCostaFF.Increased adhesive properties of neutrophils in sickle cell disease may be reversed by pharmacological nitric oxide donation. Haematologica2008;
93:605–9
55.
AlmeidaCBSouzaLELeonardoFCCosta FT, Werneck CC, Covas DT, Costa FF, Conran N.
Acute hemolytic vascular inflammatory processes are prevented by nitric oxide replacement or a single dose of hydroxyurea. Blood2015; 126:711-20
56.
VinjamurDSBauerDEOrkinSH.Recent progress in understanding and manipulating haemoglobin switching for the haemoglobinopathies. Br J Haematol2018;
180:630–43
57.
HabaraAHShaikhoEMSteinbergMH.Fetal hemoglobin in sickle cell anemia: the Arab-Indian haplotype and new therapeutic agents. Am J Hematol2017;
92:1233–42
58.
BauerDEOrkinSH.Hemoglobin switching's surprise: the versatile transcription factor BCL11A is a master repressor of fetal hemoglobin. Curr Opin Genet Dev2015;
33:62–70
59.
IkutaTAusendaSCappelliniMD.Mechanism for fetal globin gene expression: role of the soluble guanylate cyclase-cGMP-dependent protein kinase pathway. Proc Natl Acad Sci U S A2001;
98:1847–52
60.
CokicVPSmithRDBeleslin-CokicBBNjoroge JM, Miller JL, Gladwin MT, Schechter AN.
Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase. J Clin Invest2003;
111:231–9
61.
ConranNOresco-SantosCAcostaHCFattoriASaadSTCostaFF.Increased soluble guanylate cyclase activity in the red blood cells of sickle cell patients. Br J Haematol2004;
124:547–54
62.
Cortese-KrottMMMergiaEKramerCMLückstädt W, Yang J, Wolff G, Panknin C, Bracht T, Sitek B, Pernow J, Stasch JP, Feelisch M, Koesling D, Kelm M.
Identification of a soluble guanylate cyclase in RBCs: preserved activity in patients with coronary artery disease. Redox Biol2018;
14:328–37
63.
KeeferJRSchneidereithTAMaysAPurvisSHDoverGJSmithKD.Role of cyclic nucleotides in fetal hemoglobin induction in cultured CD34+ cells. Exp Hematol2006;
34:1151–61
64.
IkutaTKuroyanagiYOdoNLiuS.A common signaling pathway is activated in erythroid cells expressing high levels of fetal hemoglobin: a potential role for cAMP-elevating agents in beta-globin disorders. J Blood Med2013;
4:149–59
65.
CharacheSBartonFBMooreRD, Terrin ML, Steinberg MH, Dover GJ, Ballas SK, McMahon RP, Castro O, Orringer EP.
Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive “switching” agent. The multicenter study of hydroxyurea in sickle cell anemia. Medicine1996;
75:300–26
66.
CharacheSTerrinMLMooreRD Dover GJ, Barton FB, Eckert SV, McMahon RP, Bonds DR.
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the multicenter study of hydroxyurea in sickle cell anemia. N Engl J Med1995;
332:1317–22
67.
PlattOSOrkinSHDoverGBeardsleyGPMillerBNathanDG.Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin Invest1984;
74:652–6
68.
SteinbergMHBartonFCastroOPegelow CH, Ballas SK, Kutlar A, Orringer E, Bellevue R, Olivieri N, Echman J, Varma M, Ramirez G, Adler B, Smith W, Carlos T, Ataga K, DeCastro L, Bigelow C, Saunthararajah Y, Telfer M, Vichinsky E, Claster S, Shurin S, Bridges S, Waclawiw M, Bonds D, Terrin M.
Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA2003;
289:1645–51
69.
WareREAygunB.Advances in the use of hydroxyurea. Hematology Am Soc Hematol Educ Program2009;1:62–9
70.
BerthautIBachirDKottiSChalas C, Stankovic K, Eustache F, Ravel C, Habibi A, Brailly-Tabard S, Lévy-Dutel L, Bleibtreu A, Simon T, Galactéros F, Lionnet F, Mandelbaum J.
Adverse effect of hydroxyurea on spermatogenesis in patients with sickle cell anemia after 6 months of treatment. Blood2017;
130:2354–6
FraserDILiuKTReidBJHawkins E, Sevier A, Pyle M, Robinson JW, Ouellette PH, Ballantyne JS.
Widespread natural occurrence of hydroxyurea in animals. PLoS One2015;
10:e0142890
73.
KettaniTCottonFGulbisBFersterAKumpsA.Plasma hydroxyurea determined by gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci2009;
877:446–50
74.
SinghAXuYJ.The cell killing mechanisms of hydroxyurea. Genes2016;
7:99
75.
Kim-ShapiroDBKingSBShieldsHKolibashCPGravattWL, BallasSK.The reaction of deoxy-sickle cell hemoglobin with hydroxyurea. Biochim Biophys Acta1999;
1428:381–7
76.
PacelliRTairaJCookJAWinkDAKrishnaMC.Hydroxyurea reacts with heme proteins to generate nitric oxide. Lancet1996;
347:900
77.
GladwinMTShelhamerJHOgnibeneFPPease-Fye ME, Nichols JS, Link B, Patel DB, Jankowski MA, Pannell LK, Schechter AN, Rodgers GP.
Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease. Br J Haematol2002;
116:436–44
78.
KingSB.The nitric oxide producing reactions of hydroxyurea. Curr Med Chem2003;
10:437–52
79.
CokicVPBeleslin-CokicBBTomicMStojilkovicSSNoguchiCTSchechterAN.Hydroxyurea induces the eNOS-cGMP pathway in endothelial cells. Blood2006;
108:184–91
80.
HuangJKim-ShapiroDBKingSB.Catalase-mediated nitric oxide formation from hydroxyurea. J Med Chem2004;
47:3495–501
81.
HuangJSommersEMKim-ShapiroDBKingSB.Horseradish peroxidase catalyzed nitric oxide formation from hydroxyurea. J Am Chem Soc2002;
124:3473–80
82.
CokicVPAndricSAStojilkovicSSNoguchiCTSchechterAN.Hydroxyurea nitrosylates and activates soluble guanylyl cyclase in human erythroid cells. Blood2008;
111:1117–23
83.
NahavandiMTavakkoliFWycheMQPerlinEWinterWPCastroO.Nitric oxide and cyclic GMP levels in sickle cell patients receiving hydroxyurea. Br J Haematol2002;
119:855–7
84.
Martinez-RuizRMontero-HuertaPHromiJHeadCA.Inhaled nitric oxide improves survival rates during hypoxia in a sickle cell (SAD) mouse model. Anesthesiology2001;
94:1113–8
85.
de FranceschiLBaronAScarpaAAdrie C, Janin A, Barbi S, Kister J, Rouyer-Fessard P, Corrocher R, Leboulch P, Beuzard Y.
Inhaled nitric oxide protects transgenic SAD mice from sickle cell disease-specific lung injury induced by hypoxia/reoxygenation. Blood2003;
102:1087–96
86.
WeinerDLHibberdPLBetitPCooperABBotelhoCABrugnaraC.Preliminary assessment of inhaled nitric oxide for acute vaso-occlusive crisis in pediatric patients with sickle cell disease. JAMA2003;
289:1136–42
87.
HeadCASwerdlowPMcDadeWAJoshi RM, Ikuta T, Cooper ML, Eckman JR.
Beneficial effects of nitric oxide breathing in adult patients with sickle cell crisis. Am J Hematol2010;
85:800–2
88.
DasguptaTHebbelRPKaulDK.Protective effect of arginine on oxidative stress in transgenic sickle mouse models. Free Radic Biol Med2006;
41:1771–80
89.
MorrisCRMorrisSMJr.HagarWVan Warmerdam J, Claster S, Kepka-Lenhart D, Machado L, Kuypers FA, Vichinsky EP.
Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease?Am J Respir Crit Care Med2003;
168:63–9.
90.
MorrisCRVichinskyEPvan WarmerdamJMachado L, Kepka-Lenhart D, Morris SM Jr, Kuypers FA.
Hydroxyurea and arginine therapy: impact on nitric oxide production in sickle cell disease. J Pediatr Hematol Oncol2003;
25:629–34
91.
MorrisCRKuypersFALavrishaLAnsari M, Sweeters N, Stewart M, Gildengorin G, Neumayr L, Vichinsky EP.
A randomized, placebo-controlled trial of arginine therapy for the treatment of children with sickle cell disease hospitalized with vaso-occlusive pain episodes. Haematologica2013;
98:1375–82
92.
LittleJAHauserKPMartyrSEHarris A, Maric I, Morris CR, Suh JH, Taylor J, Castro O, Machado R, Kato G, Gladwin MT.
Hematologic, biochemical, and cardiopulmonary effects of L-arginine supplementation or phosphodiesterase 5 inhibition in patients with sickle cell disease who are on hydroxyurea therapy. Eur J Haematol2009;
82:315–21
93.
WajihNBasuSJailwalaAKim HW, Ostrowski D, Perlegas A, Bolden CA, Buechler NL, Gladwin MT, Caudell DL, Rahbar E, Alexander-Miller MA, Vachharajani V, Kim-Shapiro DB.
Potential therapeutic action of nitrite in sickle cell disease. Redox Biol2017;
12:1026–39
MiguelLIAlmeidaCBTrainaFCanalli AA, Dominical VM, Saad ST, Costa FF, Conran N.
Inhibition of phosphodiesterase 9A reduces cytokine-stimulated in vitro adhesion of neutrophils from sickle cell anemia individuals. Inflam Res2011;
60:633–42
96.
ClaudinoMAFranco-PenteadoCFCoratMAGimenes AP, Passos LA, Antunes E, Costa FF.
Increased cavernosal relaxations in sickle cell mice priapism are associated with alterations in the NO-cGMP signaling pathway. J Sex Med2009;
6:2187–96
97.
SandnerP.From molecules to patients: exploring the therapeutic role of soluble guanylate cyclase stimulators. Biol Chem2018;
399:679–90
98.
WeirNAConreyALewisDMehariA.Riociguat use in sickle cell related chronic thromboembolic pulmonary hypertension: a case series. Pulm Circ2018;
8:1–7;
99.
HillNSRahaghiFFSoodNFreyRGhofraniHA.Individual dose adjustment of riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Respir Med2017;
129:124–9
100.
MiyashiroJPantPTchernychevBMilne TG, Currie MG, Graul RM, Masferrer J.
The effect of the soluble guanylyl cyclase stimulator olinciguat on ƴ-globin gene induction in K562 cells. Blood2018;
132:1078
101.
TchernychevBFeilSGermanoPWarren W, Lonie E, Feil R, Milne TG, Hadcock J, Chien Y, Currie MG, Graul RM.
The clinical-stage sgc stimulator IW-1701 prevents increase of plasma biomarkers of intravascular inflammation and suppresses leukocyte-endothelial interactions in tnfα-treated mice. Blood2017;
130:447
102.
PotokaKPWoodKCBaustJJBueno M, Hahn SA, Vanderpool RR, Bachman T, Mallampalli GM, Osei-Hwedieh DO, Schrott V, Sun B, Bullock GC, Becker-Pelster EM, Wittwer M, Stampfuss J, Mathar I, Stasch JP, Truebel H, Sandner P, Mora AL, Straub AC, Gladwin MT.
Nitric oxide-independent soluble guanylate cyclase activation improves vascular function and cardiac remodeling in sickle cell disease. Am J Respir Cell Mol Biol2018;
58:636–47
103.
FerreiraWAJrChweihHBritoPLAlmeida CB, Penteado CF, Saad STO, Costa FF, Frenette PS, Brockschnieder D, Stasch JP, Sander P, Conran N.
The soluble guanylyl cyclase activator, BAY60-2770, abrogates leukocyte adhesion and recruitment in sickle cell disease: in vitro and in vivo studies. BMC Pharmacol Toxicol2017;
64:A70
104.
BivalacquaTJMusickiBHsuLLBerkowitzDEChampionHCBurnettAL.Sildenafil citrate-restored eNOS and PDE5 regulation in sickle cell mouse penis prevents priapism via control of oxidative/nitrosative stress. PLoS One2013;
8:e68028
105.
BialeckiESBridgesKR.Sildenafil relieves priapism in patients with sickle cell disease. Am J Med2002;
113:252
106.
BurnettALAneleUATrueheartINStrouseJJCasellaJF.Randomized controlled trial of sildenafil for preventing recurrent ischemic priapism in sickle cell disease. Am J Med2014;
127:664–8
107.
MachadoRFBarstRJYovetichNAHassell KL, Kato GJ, Gordeuk VR, Gibbs JD, Little JA, Schraufnagel DE, Krishnamurti L, Girgis RE, Morris CR, Rosenzweig EB, Badesch DB, Lanzkron S, Onyekwere O, Castro OL, Sachdev V, Waclawiw MA, Woolson R, Goldsmith JC, Gladwin MT, walk-PHaSST Investigators and Patients.
Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. Blood2011;
118:855–64
108.
AlmeidaCBTrainaFLanaroCCanalli AA, Saad ST, Costa FF, Conran N.
High expression of the cGMP-specific phosphodiesterase, PDE9A, in sickle cell disease (SCD) and the effects of its inhibition in erythroid cells and SCD neutrophils. Br J Haematol2008;
142:836–44
109.
AlmeidaCBScheiermannCJangJEProphete C, Costa FF, Conran N, Frenette PS.
Hydroxyurea and a cGMP-amplifying agent have immediate benefits on acute vaso-occlusive events in sickle cell disease mice. Blood2012;
120:2879–88
110.
JasujaRParksEMurphyJEPittmanDD.Chronic administration of the PDE9 inhibitor PF-04447943 reduces leukocyte-platelet aggregates and markers of endothelial activation in a mouse model of sickle cell disease. Blood2016;
128:1293
111.
CharnigoRJHowardJBeidlerDRybin D, Tan B, Michelson AD, Frelinger III AL, Clarke N.
A phase 1b, randomized, double-blind, placebo-controlled study of PF-04447943 in patients with stable sickle cell disease: changes in exploratory biomarkers. Blood2017;
130:974
112.
McArthurJGMacielTChenC.A novel, highly potent and selective pde9 inhibitor for the treatment of sickle cell disease. Blood2016;
128:268 [Mismatch]
113.
GladwinMTSchechterANShelhamerJHPannell LK, Conway DA, Hrinczenko BW, Nichols JS, Pease-Fye ME, Noguchi CT, Rodgers GP, Ognibene FP.
Inhaled nitric oxide augments nitric oxide transport on sickle cell hemoglobin without affecting oxygen affinity. J Clin Invest1999;
104:937–45
114.
GladwinMTKatoGJWeinerDOnyekwere OC, Dampier C, Hsu L, Hagar RW, Howard T, Nuss R, Okam MM, Tremonti CK, Berman B, Villella A, Krishnamurti L, Laznkron S, Castro O, Gordeuk VR, Coles WA, Peters-Larwrence M, Nichols J, Hall MK, Hildesheim M, Blackwelder WC, Baldassare J, Casella JF.
Nitric oxide for inhalation in the acute treatment of sickle cell pain crisis: a randomized controlled trial. JAMA2011;
305:893–902
115.
MaitreBDjibreMKatsahianSHabibi A, Stankovic Stojanovic K, Khelaff M, Bourgeon I, Lionnet F, Charles-Nelson A, Brochard L, Lemaire F, Galacteros F, Brun-Buisson C, Fartoukh M, Mekontso Dessap A.
Inhaled nitric oxide for acute chest syndrome in adult sickle cell patients: a randomized controlled study. Intensive Care Med2015;
41:2121–9
116.
MorrisCRKuypersFALarkinSVichinskyEPStylesLA.Patterns of arginine and nitric oxide in patients with sickle cell disease with vaso-occlusive crisis and acute chest syndrome. J Pediatr Hematol Oncol2000;
22:515–20
117.
MorrisCRKuypersFALarkinSSweeters N, Simon J, Vichinski EP, Styles LA.
Arginine therapy: a novel strategy to induce nitric oxide production in sickle cell disease. Br J Haematol2000;
111:498–500
118.
DejamAHunterCJTremontiCPluta RM, Hon YY, Grimes G, Partovi K, Pelletier MM, Oldfield EH, Cannon RO 3rd, Schechter AN, Gladwin MT.
Nitrite infusion in humans and nonhuman primates: endocrine effects, pharmacokinetics, and tolerance formation. Circulation2007;
116:1821–31
119.
Kim-ShapiroDBGladwinMTPatelRPHoggN.The reaction between nitrite and hemoglobin: the role of nitrite in hemoglobin-mediated hypoxic vasodilation. J Inorg Biochem2005;
99:237–46
120.
GladwinMTGrubinaRDoyleMP.The new chemical biology of nitrite reactions with hemoglobin: R-state catalysis, oxidative denitrosylation, and nitrite reductase/anhydrase. Acc Chem Res2009;
42:157–67
121.
MunzelTDaiberA.Inorganic nitrite and nitrate in cardiovascular therapy: a better alternative to organic nitrates as nitric oxide donors?Vascul Pharmacol2018;
102:1–10
122.
ChenKPiknovaBPittmanRNSchechterANPopelAS.Nitric oxide from nitrite reduction by hemoglobin in the plasma and erythrocytes. Nitric Oxide2008;
18:47–60
123.
GrubinaRBasuSTisoMKim-ShapiroDBGladwinMT.Nitrite reductase activity of hemoglobin S (sickle) provides insight into contributions of heme redox potential versus ligand affinity. J Biol Chem2008;
283:3628–38
124.
BreitensteinSRoessigLSandnerPLewisKS.Novel sGC stimulators and sGC activators for the treatment of heart failure. Handbook Exp Pharmacol2017;
243:225–47
125.
FollmannMGriebenowNHahnMGHartung I, Mais FJ, Mittendorf J, Schäter M, Schirok H, Stasch JP, Stoll F, Straub A.
The chemistry and biology of soluble guanylate cyclase stimulators and activators. Angew Chem Int Ed Engl2013;
52:9442–62
WuCCKoFNKuoSCLeeFYTengCM.YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase. Br J Pharmacol1995;
116:1973–8
128.
KoFNWuCCKuoSCLeeFYTengCM.YC-1, a novel activator of platelet guanylate cyclase. Blood1994;
84:4226–33
129.
MakowskiCTRissmillerRWBullingtonWM.Riociguat: a novel new drug for treatment of pulmonary hypertension. Pharmacotherapy2015;
35:502–19
130.
ArmstrongPWRoessigLPatelMJAnstrom KJ, Butler J, Voors AA, Lam CSP, Ponikowski P, Temple T, Pieske B, Ezekowitz J, Hernandez AF, Koglin J, O'Connor CM.
A multicenter, randomized, double-blind, placebo-controlled trial of the efficacy and safety of the oral soluble guanylate cyclase stimulator: the VICTORIA trial. JACC Heart Fail2018;
6:96–104
131.
MittlemanRSWilsonPSykesKMihova M, Chickering JG, Ruff D, Hall M, Milne TG, Currie MG, Chien Y.
Multiple-ascending-dose study of the soluble guanylate cyclase stimulator, IW-1701, in healthy subjects. Blood2017;
130:3533
ZhouZPyriochouAKotanidouADalkas G, van Eickels M, Spyroulias G, Roussos C, Papapetropoulos A.
Soluble guanylyl cyclase activation by HMR-1766 (ataciguat) in cells exposed to oxidative stress. Am J Physiol Heart Circ Physiol2008;
295:H1763–71
134.
StaschJPSchmidtPAlonso-AlijaCApeler H, Dembowsky K, Haerter M, Heil M, Minuth T, Perzborn E, Pleiss U, Schramm M, Schroeder W, Schröder H, Stahl E, Steinke W, Wunder F.
NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle. Br J Pharmacol2002;
136:773–83
135.
StaschJPSchlossmannJHocherB.Renal effects of soluble guanylate cyclase stimulators and activators: a review of the preclinical evidence. Curr Opin Pharmacol2015;
21:95–104
136.
EvgenovOVPacherPSchmidtPMHaskoGSchmidtHHStaschJP.NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov2006;
5:755–68
137.
DumitrascuRWeissmannNGhofraniHADony E, Beuerlein K, Schmidt H, Stasch JP, Gnoth MJ, Seeger W, Grimminger F, Schermuly RT.
Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling. Circulation2006;
113:286–95
138.
ErdmannESemigranMJNieminenMSGheorghiade M, Agrawal R, Mitrovic V, Mebazaa A.
Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure. Eur Heart J2013;
34:57–67
139.
SchaferAFraccarolloDWernerLBauersachsJ.Guanylyl cyclase activator ataciguat improves vascular function and reduces platelet activation in heart failure. Pharmacol Res2010;
62:432–8
140.
LeeKHLeeSRChoHWoo JS, Kang JH, Jeong YM, Cheng XW, Kim WS, Kim W.
Cardioprotective effects of PKG activation by soluble GC activator, BAY 60-2770, in ischemia-reperfusion-injured rat hearts. PLoS One2017;
12:e0180207
141.
RomoliSBauchTDröbnerKEitnerF.Evaluation of kidney protection of soluble guanylate cyclase (sGC) modulators in a novel, fast mouse model. BMC Pharmacol Toxicol2017;
18:A55
142.
HaririEMansourAEl AlamADaaboulYKorjianSAoun BahousS.Sickle cell nephropathy: an update on pathophysiology, diagnosis, and treatment. Int Urol Nephrol2018;
50:1075–83
143.
SommerASandnerPBehrendsS.BAY 60-2770 activates two isoforms of nitric oxide sensitive guanylyl cyclase: evidence for stable insertion of activator drugs. Biochem Pharmacol2018;
147:10–20
144.
PotokaKPGladwinMT.Vasculopathy and pulmonary hypertension in sickle cell disease. Am J Physiol Lung Cell Mol Physiol2015;
308:L314–24
145.
PengTGongJJinYZhou Y, Tong R, Wei X, Bai L, Shi J.
Inhibitors of phosphodiesterase as cancer therapeutics. Eur J Med Chem2018;
150:742–56
LinCSLauATuRLueTF.Expression of three isoforms of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in human penile cavernosum. Biochem Biophys Res Commun2000;
268:628–35
148.
MurrayFMacLeanMRPyneNJ.Increased expression of the cGMP-inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension. Br J Pharmacol2002;
137:1187–94
149.
LeeAJChiaoTBTsangMP.Sildenafil for pulmonary hypertension. Ann Pharmacother2005;
39:869–84
150.
MachadoRFMartyrSKatoGJBarst RJ, Anthi A, Robinson MR, Hunter L, Coles W, Nicols J, Hunter C, Sachdev V, Castro O, Gladwin MT.
Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension. Br J Haematol2005;
130:445–53
151.
SinghNPatraS.Phosphodiesterase 9: insights from protein structure and role in therapeutics. Life Sci2014;
106:1–11
152.
WunderFTersteegenARebmannAErbCFahrigTHendrixM.Characterization of the first potent and selective PDE9 inhibitor using a cGMP reporter cell line. Mol Pharmacol2005;
68:1775–81
153.
CuryYPicoloGGutierrezVPFerreiraSH.Pain and analgesia: the dual effect of nitric oxide in the nociceptive system. Nitric Oxide2011;
25:243–54
154.
LatremoliereAWoolfCJ.Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J Pain2009;
10:895–926
155.
KhouriCLepelleyMRoustitMMontastrucFHumbertMCracowskiJL.Comparative safety of drugs targeting the nitric oxide pathway in pulmonary hypertension: a mixed approach combining a meta-analysis of clinical trials and a disproportionality analysis from the world health organization pharmacovigilance database. Chest2018;
154:136–47
156.
NiiharaYMillerSTKanterJLanzkron S, Smith WR, Hsu LL, Gordeuk VR, Viswanathan K, Sarnaik S, Osunkwo I, Guillaume E, Sadanandan S, Sieger L, Lasky JL, Panosyan EH, Blake OA, New TN, Bellevue R, Tran LT, Razon RL, Stark CW, Neumayr LD, Vichinsky EP, Investigators of the Phase 3 Trial of I-Glutamine in Sickle Cell Disease.
A phase 3 trial of l-glutamine in sickle cell disease. N Engl J Med2018;
379:226–35
157.
AtagaKIKutlarAKanterJLiles D, Cancado R, Friedrisch J, Guthrie TH, Knight-Madden J, Alvarez OA, Gordeuk VR, Gualandro S, Colella MP, Smith WR, Rollins SA, Stocker JW, Rother RP.
Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med2017;
376:429–39.
